GLP-2 Analogs Market Technology Advancements and Growth Trends 2034

The GLP-2 analogs market is gaining traction due to its clinical effectiveness in treating rare gastrointestinal diseases. The increasing incidence of intestinal failure and the growing need for long-term nutritional support solutions are key contributors to market expansion. Additionally, the growing pipeline of innovative GLP-2 analog therapies is expected to boost market growth in the coming years. The market is also benefiting from improved healthcare infrastructure, rising investment in biotechnology research, and the increasing availability of orphan drug designations. These factors are collectively enhancing the accessibility and development of GLP-2-based treatments globally.

The global GLP-2 Analogs Market Growth in 2026 is witnessing steady expansion, driven by rising awareness of gastrointestinal disorders and increasing demand for advanced biologic therapies. According to Fortune Business Insights, the global GLP-2 analogs market size was valued at USD 1.20 billion in 2025. The market is projected to grow from USD 1.83 billion in 2026 to USD 2.65 billion by 2034, exhibiting a CAGR of 6.08% during the forecast period. The market growth reflects the increasing adoption of targeted treatments and advancements in peptide-based therapeutics.

GLP-2 analogs are synthetic versions of glucagon-like peptide-2, a hormone that plays a critical role in intestinal growth, nutrient absorption, and gut function. These therapies are primarily used in the treatment of short bowel syndrome (SBS) and other intestinal disorders, improving patient outcomes and quality of life.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 & 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:

Drivers:

• Increasing prevalence of short bowel syndrome and gastrointestinal disorders

• Rising demand for advanced biologic and peptide-based therapies

• Growing focus on orphan drug development and rare disease treatment

• Strong clinical pipeline for long-acting GLP-2 analogs

• Improved patient outcomes and reduced dependency on parenteral nutrition

Restraints:

• High cost of GLP-2 analog therapies

• Limited awareness in emerging markets

• Regulatory challenges associated with biologics

• Restricted patient pool due to rarity of target conditions

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲:

The report provides a comprehensive analysis of the GLP-2 analogs market, covering key aspects such as market size, growth trends, competitive landscape, and regional insights. It includes detailed segmentation, emerging trends, and strategic developments shaping the industry. The report also highlights regulatory frameworks, product approvals, and pipeline analysis, offering a holistic view of market dynamics.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

The GLP-2 analogs market is moderately consolidated, with key players focusing on research and development, strategic collaborations, and product innovation. Companies are investing heavily in clinical trials and expanding their product portfolios to gain a competitive edge.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗜𝗻 𝗧𝗵𝗲 Market

• Takeda Pharmaceutical Company Limited (Japan)

• OxThera (Sweden)

• Zealand Pharma (Denmark)

• Ironwood (U.S.)

• Hanmi Pharm Co., Ltd. (South Korea)

• Jaguar Health (U.S.)

• Merck KGaA (Germany)

• EnteraBio Ltd. (Israel)

• Nestlé (Switzerland)

These companies are focusing on developing long-acting GLP-2 analogs and expanding their geographic presence to strengthen their market position.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀:

The GLP-2 analogs market can be segmented based on 

By Drug (Teduglutide and Others), By Route of Administration (Oral and Parenteral)

By Distribution Channel (Hospital Pharmacies and Online & Retail Pharmacies)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/glp-2-analogs-market-113558 

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:

North America dominated the GLP-2 analogs market with a market share of 77.11% in 2025. The region’s leadership is attributed to advanced healthcare infrastructure, high adoption of innovative therapies, and strong presence of key market players.

Europe is expected to witness steady growth due to increasing regulatory approvals and rising awareness about rare gastrointestinal conditions. Favorable reimbursement policies are also supporting market expansion in the region.

Asia Pacific is anticipated to grow at a notable pace during the forecast period, driven by improving healthcare systems, increasing investments in biotechnology, and rising patient awareness.

Rest of the World is gradually expanding with increased access to advanced therapies and growing healthcare initiatives.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲:

The future of the GLP-2 analogs market looks promising, with ongoing research focused on enhancing drug efficacy and extending treatment duration. The development of next-generation GLP-2 analogs with improved pharmacokinetic profiles is expected to drive market growth.

Additionally, increasing collaboration between pharmaceutical companies and research institutions is likely to accelerate innovation. The growing emphasis on personalized medicine and targeted therapies will further expand the application scope of GLP-2 analogs.

Digital health integration and remote patient monitoring are also expected to play a significant role in improving treatment adherence and outcomes, contributing to overall market development.

Recent Industry Developments

• June 2025: Zealand Pharma A/S submitted a marketing authorization application (MAA) for glepaglutide, a long-acting GLP-2 analog, to the European Medicines Agency (EMA).

• March 2024: Ironwood Pharmaceuticals announced the positive result for the phase 2 exploratory stargaze trial of Apraglutide, a long-acting GLP-2 analog used to treat patients with steroid-refractory gastrointestinal acute graft-versus-host disease.

Conclusion

The GLP-2 analogs market is set for consistent growth, driven by technological advancements, increasing prevalence of gastrointestinal disorders, and rising demand for effective treatment options. With strong regional dominance by North America and emerging opportunities in Asia Pacific, the market is poised for significant expansion through 2034.

Continuous innovation, strategic partnerships, and supportive regulatory frameworks will be key factors shaping the future of this market. As research progresses and new therapies enter the market, GLP-2 analogs are expected to play a crucial role in transforming gastrointestinal disease management.

Contact us:

Fortune Business Insights™ Pvt.Phone: USA: +1 833 909 2966 (Toll-Free),United Kingdom: +44 808 502 0280 (Toll-Free),APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com